SequelSEC

Celldex Therapeutics, Inc. CLDX

In Vitro & In Vivo Diagnostic Substances · CIK 0000744218 · Fiscal year ends 1231

Revenue
$158.00K
Fiscal year ended 2026-06-30
Operating income
-$325.83M
Fiscal year ended 2026-06-30
Free cash flow
-$242.10M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.30BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$19.53Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue841.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the In Vitro & In Vivo Diagnostic Substances filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio10.49x100th
R&D / revenue15862.4%100th
Revenue YoY growth-78.0%0th
SBC / revenue2344.1%100th
Net margin-16748.0%8th
Operating margin-18599.8%8th
CapEx / revenue175.7%89th
FCF margin-13829.1%11th
Gross margin87.1%89th

Celldex Therapeutics, Inc. (CLDX) reported revenue of $158.00K and net income of -$300.55M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Celldex Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

Celldex Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$158.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$325.83M
Net income-$300.55M
Research & development$278.81M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$47.18M
Selling & marketingUnavailable

Balance

Celldex Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$47.45M
Total assets$782.35M
Current assets$724.93M
Total liabilities$67.78M
Current liabilities$61.32M
Total equity incl. NCI$714.56M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$14.68M

Cash flow

Celldex Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$235.57M
Capital expenditures$6.54M
Investing cash flow-$67.13M
Financing cash flow$327.11M
Net change in cash$24.41M
Stock-based compensation$34.64M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$3.40M

Derived

Celldex Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$242.10M
Gross marginUnavailable
Operating margin-206220.3%
FCF margin-153231.0%
SBC / revenue21924.7%
Current ratio11.82x
Revenue YoY growth-97.3%
Net margin-190220.9%
R&D / revenue176460.1%
CapEx / revenue4138.6%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CLDX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.